» Articles » PMID: 31847232

The Correlation of Central Serous Chorioretinopathy and Subsequent Cardiovascular Diseases of Different Types: A Population-Based Cohort Study

Overview
Publisher MDPI
Date 2019 Dec 19
PMID 31847232
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of the present study was to survey the relationship between central serous chorioretinopathy (CSC) and several cardiovascular diseases (CVDs) with different severities using the National Health Insurance Research Database. A retrospective cohort study was conducted. Subjects with CSC were enrolled according to the relevant diagnostic codes, and an age- and gender-matched population was used as the control group with a 1:4 ratio. The main outcome being considered was the development of CVD after CSC exposure. Cox proportional hazard regression was applied to calculate the adjusted hazard ratio (aHR) of CSC and CVD of different types. A total of 2865 patients that were diagnosed with CSC were enrolled in the study group, while another 11,460 non-CSC subjects were selected as the control group. There were 171 events of CVD which occurred in the study group, while another 557 cases were found in the control group. No significant differences were observed among the CVD cases between the study and control group, whether they had an acute or chronic form, according to the aHR. In the subgroup analysis, there was a significantly higher risk of CVD development in the male population aged from 40 to 59 years (aHR: 1.351, confidence interval (CI): 1.063-1.716), which was mainly due to the higher risk of mild CVD (aHR: 1.391, CI: 1.062-1.822). On the contrary, there was no significant difference in CVD development in any of the age subgroups of the female population. In conclusion, the existence of CSC is correlated with a higher rate of chronic CVD occurrence in the middle-aged male population.

Citing Articles

Increased oxidative stress biomarkers in central serous chorioretinopathy.

Ercin Akidan E, Yilmaz E, Yilmaz N, Akidan M Sci Rep. 2024; 14(1):21099.

PMID: 39256410 PMC: 11387491. DOI: 10.1038/s41598-024-71890-6.


Central serous chorioretinopathy: Pathophysiology, systemic associations, and a novel etiological classification.

Jain M, Mohan S, van Dijk E Taiwan J Ophthalmol. 2023; 12(4):381-393.

PMID: 36660127 PMC: 9843580. DOI: 10.4103/2211-5056.362601.


New Insights in Prevention and Treatment of Cardiovascular Disease.

Di Raimondo D, Musiari G, Rizzo G, Pirera E, Signorelli S Int J Environ Res Public Health. 2022; 19(4).

PMID: 35206661 PMC: 8872199. DOI: 10.3390/ijerph19042475.


Intima-Media Thickness Measurements of the Common Carotid Artery in Patients with Central Serous Chorioretinopathy: A Case-Control Study.

Nasrollahi K, Farahi A, Paknazar F, Akhlaghi M, Fazel F, Zarepur E J Ophthalmol. 2021; 2021:6652373.

PMID: 34527376 PMC: 8437640. DOI: 10.1155/2021/6652373.


Nailfold Videocapillaroscopy in Patients with Central Serous Chorioretinopathy and Its Relationship to Morphological and Functional Findings.

Latalska M, Bartosinska J, Kosior-Jarecka E, Krasowska D, Mackiewicz J J Clin Med. 2020; 9(12).

PMID: 33265997 PMC: 7759800. DOI: 10.3390/jcm9123891.

References
1.
Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N . Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015; 48:82-118. DOI: 10.1016/j.preteyeres.2015.05.003. View

2.
Caccavale A, Romanazzi F, Imparato M, Negri A, Morano A, Ferentini F . Central serous chorioretinopathy: a pathogenetic model. Clin Ophthalmol. 2011; 5:239-43. PMC: 3046994. DOI: 10.2147/OPTH.S17182. View

3.
Garcia-Horton A, Al-Ani F, Lazo-Langner A . Retinal vein thrombosis: The Internist's role in the etiologic and therapeutic management. Thromb Res. 2016; 148:118-124. DOI: 10.1016/j.thromres.2016.11.004. View

4.
Yun C, Huh J, Ahn S, Lee B, Kim J, Hwang S . Choriocapillaris flow features and choroidal vasculature in the fellow eyes of patients with acute central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2018; 257(1):57-70. DOI: 10.1007/s00417-018-4179-2. View

5.
Du X, Patel A, Anderson C, Dong J, Ma C . Epidemiology of Cardiovascular Disease in China and Opportunities for Improvement: JACC International. J Am Coll Cardiol. 2019; 73(24):3135-3147. DOI: 10.1016/j.jacc.2019.04.036. View